难治性肾病综合征环孢素A血药浓度监测结果分析  

Therapeutic drug monitoring of cyclosporine A in patients with nephrotic syndrome

作　　者：贾暖[1] 张莉[1] 刘洋[1] 董玉波[1] 

机构地区：[1]济南军区总医院药剂科,济南250031

出　　处：《临床药物治疗杂志》2015年第3期72-74,共3页Clinical Medication Journal

摘　　要：目的：对济南军区总医院3年期间住院难治性肾病综合征患者全血中环孢素A（Cs A）浓度的监测结果加以分析,以便探讨其临床有效性和安全性,为更好地开展Cs A浓度监测提供参考。方法：采用荧光偏振免疫法测定92例肾病综合征患者的224次环孢素谷浓度,分析Cs A血药浓度与临床疗效及合并用药之间的关系。结果：92例难治性肾病综合征患者监测Cs A浓度共224例次,平均血药浓度为（134.78±65.26）ng·m L^-1（·x±s）,达有效浓度（100-150ng·m L^-1）152例次（67.86%）,低于100 ng·m L^-1有60例次（26.79%）,高于150 ng·m L^-1有12例次（5.36%）。结论：Cs A血药浓度受多种因素的影响,对肾病综合征患者进行Cs A浓度监测具有重要的临床意义。Objective： To analyze the results of cyclosporine A （CsA） whole blood concentration in the patients with nephrotic syndrome in our hospital during the last three years, and evaluate the efficacy and safety of CsA monitoring. Methods： 224 CsA whole blood samples in 92 patients with a plastic anemia were measured by means of fluorescence polarization immunoassay （FPIA）. Then the relationship between efficacy and CsA blood concentration was analyzed. Result： Total of 224 samples were measured. 152 samples （67.86%） reached the effective blood concentration range （100-150 ng·mL^-1）, 60 samples（26.79%） were lower and 12 samples （5.36%） were higher than that. The average blood concentration of CsA was（134.78± 65.26）ng.mL^-1 （n=224）. Conclusion： The factors which can affect CsA whole blood concentration were complex. Monitoring CsA blood concentration can be used to guide rational use of CsA in patients with nephrotic syndrome.

关 键 词：难治性肾病综合征 环孢素A 血药浓度 荧光偏振免疫法 个体化给药 

分 类 号：R944[医药卫生—药剂学]